

## RELUGOLIX tablets (Orgovyx® ▼) for hormone-sensitive prostate cancer

**The Cheshire and Merseyside Interim Area Prescribing Group does not currently recommend the prescribing of RELUGOLIX tablets (Orgovyx® ▼) for hormone-sensitive prostate cancer.**

### GREY

Relugolix is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.<sup>[1]</sup>

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, clinicians should continue to follow national guidance, local pathways, and local formulary choices for prostate cancer:

- > NICE Guideline [NG131]: [Prostate cancer: diagnosis and management](#) (updated 15 December 2021)
- > NICE Clinical Knowledge Summary [Prostate cancer](#) (updated February 2022)
- > Cheshire APG Formulary Chapter 08.03.04.02 [Prostate cancer and gonadorelin analogues](#)
- > Pan Mersey APC Formulary Chapter 08.03.04.02 [Prostate cancer and gonadorelin analogues](#)

### References

1. Accord-UK Ltd. Summary of Product Characteristics; [Orgovyx 120 mg film-coated tablets](#), 29 July 2022. Accessed online 21 March 2023.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.